Loading...
NPI 1295077402 · Evansville, IN · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Andrew Strand is a ophthalmology physician provider located in Evansville, Indiana. This profile covers 21 Medicare and 3 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Andrew Strand |
| Address | 6149 E Columbia St |
| City | Evansville |
| State | IN |
| ZIP | 47715 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | March 26, 2013 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.3M |
| Medicaid | $72.1K |
Practice is heavily anti-VEGF/injection–driven: Medicare revenue is dominated by intravitreal biologic therapy with J0178 accounting for $2.9M (66.0% of this provider's total Medicare revenue) and J2777 contributing $903.1K (20.8%). The top three Medicare codes together account for 91.7% of Medicare revenue, indicating the operation is primarily built around high-volume injection services rather than diversified clinic or surgical lines. This billing mix is consistent with a retina-focused medical ophthalmology practice delivering repeated in-office injections.
High concentration of Medicare revenue creates single–service exposure: the precomputed figure shows the top 3 Medicare codes account for 91.7% of Medicare revenue, which concentrates financial performance on ongoing medication administration and associated injection procedures (J0178, J2777, 67028). That dependence means changes in drug mix, reimbursement, or utilization patterns for these specific codes would materially affect revenue. Clinically, this aligns with frequent recurring care (anti-VEGF/faricimab administrations) rather than episodic surgical throughput.
Medicaid billing is negligible relative to Medicare: the provider reports $4.3M in Medicare revenue versus $72.1K in Medicaid revenue, indicating Medicare is the overwhelmingly dominant payer for this clinician. Medicaid activity is also concentrated — the top three Medicaid codes account for 100.0% of the provider's Medicaid revenue — so the small Medicaid volume mirrors the injection/imaging focus seen in Medicare but at an effectively minor scale.
Competitive standing on key Medicare therapeutic codes is strong nationally: the provider ranks #61 of 3204 for J0178 in the 98th percentile and #185 of 4255 for 67028 in the 96th percentile, both noted as "notably above typical" national volume. By contrast, J2777 sits at #279 of 2039 (86th percentile, labeled typical/unremarkable), so while faricimab use is meaningful, the practice is especially high-volume for aflibercept administration. These rank percentiles indicate the provider is a major national participant for certain anti-VEGF injections and injection procedures.
Medicaid competitive position is modest within-state: for Medicaid, 67028 ranks #40 of 55 (28th percentile) and J0178 ranks #21 of 24 (13th percentile), both characterized as typical/unremarkable in-state volumes. Despite being a high-volume Medicare injector, the provider is not a leading Medicaid injector in the state, suggesting either limited Medicaid patient access or payer mix preferences in the local market. The Medicaid footprint is therefore operationally minor compared with Medicare.
Diagnostic imaging and E/M volume are notable and above typical levels: 92134 is reported at 2.6K Medicare claims with a rank in the 98th percentile and labeled an "extreme outlier, far above typical national volume," indicating heavy utilization of posterior-segment retinal imaging. In addition, E/M codes such as 99214 (808 claims, 96th percentile, "notably above typical") and 99212 (366 claims, 98th percentile, "notably above typical") show substantial outpatient visit volumes, supporting a high-visit, procedure-centric ambulatory workflow.
Surgical retina procedures are present but minor to revenue: codes such as 67036, 67108, 67042 and 67041 appear with low claim counts and modest revenues relative to injections, indicating occasional vitreoretinal surgery but not a dominant surgical practice line. Typical/unremarkable percentile placements for many surgical codes imply the practice’s clinical throughput is weighted toward in-office injections and imaging rather than frequent OR-based procedures.
Provider tenure and market implications: NPI was enumerated on 2013-03-26 (~13 years ago), reflecting a stable, established practice with more than a decade of billing history. Given the concentration in recurring intravitreal therapies and high national percentiles on key injection and imaging codes, the provider occupies a durable niche as a high-volume medical retinal injector in Medicare, with minimal Medicaid scale and a residual surgical capability.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
21 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 4,160 | $690 | $2.9M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 31,140 | $30 | $903.1K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,480 | $80 | $208.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,600 | $30 | $75.3K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 810 | $90 | $71.1K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 320 | $160 | $50.1K |
| J2778 | Injection, ranibizumab, 0.1 mg | 220 | $180 | $40.6K |
| 67036 | The provider removes vitreous fluid from the eye to access the posterior segment of the eye and introduce surgical instruments through incisions in the pars plana. | 30 | $640 | $17.9K |
| 67108 | The provider repairs a detached retina using heat produced by a laser beam or by freezing the tissues. He may attach a scleral buckle to simplify the passage of fluid through and behind the retina or… | 20 | $840 | $17.6K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 150 | $110 | $16.8K |
Showing 1–10 of 21
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
21 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 2 | 60 | 830 | $690 | $868.8K |
| J2777 | 5 | 40 | 6,750 | $30 | $395.6K |
| J2778 | 13 | 10 | 560 | $180 | $150K |
| 67028 | 6 | 80 | 550 | $80 | $78.6K |
| J7312 | 3 | 10 | 280 | $160 | $47.7K |
| 67042 | 13 | 20 | 20 | $1,310 | $47K |
| 67036 | 6 | 10 | 30 | $1,040 | $37.4K |
| 67108 | 6 | 20 | 20 | $1,150 | $32.2K |
| J3590 | 37 | 50 | 220 | $60 | $24.5K |
| 67041 | 11 | 10 | 20 | $1,000 | $22K |
Showing 1–10 of 21
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 220 | $180 | $40.3K |
| J0178 | Injection, aflibercept, 1 mg | 30 | $920 | $30.2K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 130 | $10 | $1.6K |
How this provider's Medicaid billing volume and revenue compare to other Indiana providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Indiana median
3 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 21 | 20 | 470 | $610 | $598.3K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 40 | 60 | 1,260 | $50 | $108.4K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 60 | 80 | 680 | $20 | $34.5K |
Other providers in the same ZIP code as Andrew Strand, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.